Format

Send to

Choose Destination
See comment in PubMed Commons below
PLoS One. 2014 Feb 4;9(2):e88001. doi: 10.1371/journal.pone.0088001. eCollection 2014.

A novel angiotensin I-converting enzyme mutation (S333W) impairs N-domain enzymatic cleavage of the anti-fibrotic peptide, AcSDKP.

Author information

1
Institute for Personalized Respiratory Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America ; Department of Anesthesiology, University of Illinois at Chicago, Chicago, Illinois, United States of America.
2
Institute for Personalized Respiratory Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America.
3
Institute of Infectious Disease and Molecular Medicine and Division of Medical Biochemistry, University of Cape Town, Cape Town, South Africa.
4
Department of Dermatology, Rush University, Chicago, Illinois, United States of America.
5
Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois, United States of America.
6
Department of Medicine, University of Chicago, Chicago, Illinois, United States of America.
7
Department of Anesthesiology, University of Illinois at Chicago, Chicago, Illinois, United States of America.
8
Department of Medicine, University of Arizona, Tucson, Arizona, United States of America.

Abstract

BACKGROUND:

Angiotensin I-converting enzyme (ACE) has two functional N- and C-domain active centers that display differences in the metabolism of biologically-active peptides including the hemoregulatory tetrapeptide, Ac-SDKP, hydrolysed preferentially by the N domain active center. Elevated Ac-SDKP concentrations are associated with reduced tissue fibrosis.

RESULTS:

We identified a patient of African descent exhibiting unusual blood ACE kinetics with reduced relative hydrolysis of two synthetic ACE substrates (ZPHL/HHL ratio) suggestive of the ACE N domain center inactivation. Inhibition of blood ACE activity by anti-catalytic mAbs and ACE inhibitors and conformational fingerprint of blood ACE suggested overall conformational changes in the ACE molecule and sequencing identified Ser333Trp substitution in the N domain of ACE. In silico analysis demonstrated S333W localized in the S1 pocket of the active site of the N domain with the bulky Trp adversely affecting binding of ACE substrates due to steric hindrance. Expression of mutant ACE (S333W) in CHO cells confirmed altered kinetic properties of mutant ACE and conformational changes in the N domain. Further, the S333W mutant displayed decreased ability (5-fold) to cleave the physiological substrate AcSDKP compared to wild-type ACE.

CONCLUSIONS AND SIGNIFICANCE:

A novel Ser333Trp ACE mutation results in dramatic changes in ACE kinetic properties and lowered clearance of Ac-SDKP. Individuals with this mutation (likely with significantly increased levels of the hemoregulatory tetrapeptide in blood and tissues), may confer protection against fibrosis.

PMID:
24505347
PMCID:
PMC3913711
DOI:
10.1371/journal.pone.0088001
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Support Center